We are delighted to share a new collaborative study published in ACS Omega, led by our colleagues at Martin Luther University Halle-Wittenberg. The team designed and synthesized a new class of α-amino amide–based inhibitors that selectively target HDAC11, a unique deacylase involved in metabolism, immune regulation, and cancer. The resulting compound exhibits nanomolar potency and remarkable selectivity, representing a new direction in HDAC inhibitor design beyond the traditional hydroxamic acids. Congratulations to all collaborators on this important advance in the development of next-generation HDAC11 inhibitors!
